These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26393391)

  • 1. Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.
    Hammonds T
    Future Med Chem; 2015; 7(14):1891-9. PubMed ID: 26393391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
    Palmer M; Chaguturu R
    Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
    [No Abstract]   [Full Text] [Related]  

  • 3. How academic labs can approach the drug discovery process as a way to synergize with big pharma.
    Loregian A; Palù G
    Trends Microbiol; 2013 Jun; 21(6):261-4. PubMed ID: 23731493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partnerships in Pharma--An Economist Intelligence Unit Seminar--Building Innovation into Alliances and Business Models. 1 October 2010, London, UK.
    Kibble A
    IDrugs; 2010 Dec; 13(12):813-5. PubMed ID: 21154130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaboration between academia and pharma to bring new therapies to market more important than ever.
    Caffrey MK
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E14. PubMed ID: 25764579
    [No Abstract]   [Full Text] [Related]  

  • 7. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
    Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
    Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?
    Lexchin J
    Expert Opin Drug Discov; 2021 May; 16(5):475-479. PubMed ID: 33307875
    [No Abstract]   [Full Text] [Related]  

  • 9. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The innovative medicines initiative: a case study for new ways of working in drug R&D.
    Laverty H; Goldman M
    Future Med Chem; 2014 Apr; 6(5):489-91. PubMed ID: 24649951
    [No Abstract]   [Full Text] [Related]  

  • 14. Leveraging public private partnerships to innovate under challenging budget times.
    Portilla LM; Rohrbaugh ML
    Curr Top Med Chem; 2014; 14(3):326-9. PubMed ID: 24283971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
    Yokley BH; Hartman M; Slusher BS
    ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.
    Nilsson N; Felding J
    Future Med Chem; 2015; 7(14):1853-9. PubMed ID: 26393392
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
    Ioset JR; Chang S
    Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How academia and the pharmaceutical industry can work together: the president's lecture, annual meeting of the American Thoracic Society, San Francisco, California.
    Rosenblatt M
    Ann Am Thorac Soc; 2013 Feb; 10(1):31-8. PubMed ID: 23509330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 20. Open innovation networks between academia and industry: an imperative for breakthrough therapies.
    Melese T; Lin SM; Chang JL; Cohen NH
    Nat Med; 2009 May; 15(5):502-7. PubMed ID: 19424212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.